BMS' Opdivo Gets CHMP Backing For Expanded European Label
This article was originally published in The Pink Sheet Daily
Executive Summary
Use for previously treated advanced renal cell carcinoma in adults as well as previously treated metastatic non-squamous non-small cell lung cancer, regardless of PD-L1 expression, is recommended by EMA Committee for Medicinal Products for Human Use.